Cerus rises on American Red Cross contract for blood system

Cerus

25/04/2022 13:59

** Shares of biomedical products company  CERS.O  rise
~2.04% to $4.51 premarket
    ** Co says it has signed five-year contract with the
American Red Cross for its INTERCEPT Blood System used to
produce pathogen reduced platelets  urn:newsml:reuters.com:*:nBw7Rzrp0a
    ** INTERCEPT treated platelets meet U.S. FDA's bacterial
safety requirements and protect patients against broad spectrum
of transfusion-transmitted infections - American Red Cross 
    ** As of last close, stock had lost ~35% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))